Interestingly, ASCT2 expression significantly increased in patients with recurrent prostate cancer (p < 0.001; Figure 1C), indicating either re‐activation of androgen receptor signalling or that other signalling pathways might up‐regulate ASCT2 expression upon disease recurrence. This evidence concerns the gene AR and Familial prostate cancer.